Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octavalent HPV Vaccine Dose-Ranging Study in Young Women
NCT00260039Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2005
- Primary completion
- Aug 2007
01
Overview
Phase 2, randomised, double-blind trial of octavalent HPV L1 VLP vaccine in human papillomavirus infection, Cervical Cancer (CC) and anogenital warts (4 arms), sponsored by Merck & Co. Primary endpoints: HPV type-specific immune response measured by competitive Luminex immunoassay at 7 months and Safety and tolerability of the vaccine at 7 months. Started Dec 2005; status: completed.
02
Drugs
octavalent HPV L1 VLP vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)anogenital warts
Beyond the preview
Go deeper on NCT00260039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00260039.